# Pius Hospital Oldenburg

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/pius-hospital-oldenburg/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 56 |
| Citations | 60,948 |
| City | Oldenburg |
| Country | DE |
| Description | Pius Hospital Oldenburg is a research organisation in Oldenburg, DE. OpenAlex records 1,492 works and 60,948 citations for it. 332 researchers list it as their most recent affiliation. |
| Homepage | http://www.pius-hospital.de/ |
| OpenAlex ID | https://openalex.org/I4210125974 |
| Researchers | 332 |
| ROR ID | https://ror.org/03avbdx23 |
| Type | healthcare |
| Works | 1,492 |

## University papers

- [Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease](https://scholariq.org/papers/standardized-rt-pcr-analysis-of-fusion-gene-transcripts-from-chromosome/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial](https://scholariq.org/papers/high-dose-methotrexate-with-or-without-whole-brain-radiotherapy-for-primary-cns/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)
- [Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-alk-inhibitor-naive-advanced-alk-positive-nsclc/)
- [Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-advanced-alk-inhibitor-naive-alk-positive-non/)
- [Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer](https://scholariq.org/papers/chemoradiotherapy-plus-induction-or-consolidation-chemotherapy-as-total/)
- [Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study](https://scholariq.org/papers/alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma/)
- [Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML](https://scholariq.org/papers/screening-for-mll-tandem-duplication-in-387-unselected-patients-with-aml/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy](https://scholariq.org/papers/1336p-small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-egfr/)

## University researchers

- [Frank Griesinger](https://scholariq.org/researchers/frank-griesinger/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Radiation Therapy and Dosimetry](https://scholariq.org/topics/radiation-therapy-and-dosimetry/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Uterine Myomas and Treatments](https://scholariq.org/topics/uterine-myomas-and-treatments/)
- [Total Knee Arthroplasty Outcomes](https://scholariq.org/topics/total-knee-arthroplasty-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.